Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Baptist

Hospitalist Atlantic City, NJ Medical Doctor

NPI 1982095758 CMS profile 2782599

1925 Pacific Ave, Atlantic City, NJ 08401

Open in the dashboard

General payments

$22,887

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Baptist of Atlantic City, NJ is reported in the CMS Open Payments database as having received $22,887 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,450 41
2024 General $7,036 34
2023 General $7,724 33
2022 General $115 8
2021 General $115 1
2020 General $150 4
2019 General $296 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Baptist
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Justin Baptist were reported at $7,450. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Justin Baptist Hospitalist median Middle half National median
2019 $296 $96 $28–$201 $163
2020 $150 $48 $19–$125 $114
2021 $115 $70 $23–$167 $132
2022 $115 $85 $27–$174 $149
2023 $7,724 $89 $30–$191 $160
2024 $7,036 $95 $29–$204 $164
2025 $7,450 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $21,722 74 payments
  2. Allergan Inc. $322 3 payments
  3. Merck Sharp & Dohme Corporation $173 12 payments
  4. Insmed, Inc. $125 8 payments
  5. Shionogi Inc $90 5 payments
  6. Paratek Pharmaceuticals, Inc. $89 5 payments
  7. Philips Electronics North America Corporation $77 4 payments
  8. ViiV Healthcare Company $68 4 payments
  9. La Jolla Pharmaceutical Company $60 3 payments
  10. Cumberland Pharmaceuticals, Inc. $59 4 payments
  11. Other $103 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20,450 10 payments
  2. Food and Beverage $2,424 118 payments
  3. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. DALVANCE $12,175 44 payments
  2. AVYCAZ $5,047 12 payments
  3. EMBLAVEO $4,583 5 payments
  4. TEFLARO $277 16 payments
  5. Arikayce $125 8 payments
  6. DIFICID $119 8 payments
  7. ZERBAXA $98 7 payments
  8. Fetroja $90 5 payments
  9. NUZYRA $89 5 payments
  10. MAVYRET $82 6 payments
  11. Other $626 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

166

Median for Internal Medicine: 777

Drug cost

$39,526

Median for Internal Medicine: $73,373

Branded share of claims

69.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Micafungin Micafungin Sodium Brand 12 $15,879
Ertapenem Ertapenem Sodium Brand 27 $10,209
Daptomycin Generic 37 $6,042
Fosfomycin Tromethamine Generic 14 $4,530
Sodium Chloride 0.9 % Sodium Chloride Brand 48 $1,839
Ceftriaxone Ceftriaxone Sodium Brand 28 $1,027

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$355,667

Medicare's payments for the services billed

Medicare patients

1,258

Average age 77

Services billed

4,109

630 women, 628 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 58%
Diabetes 55%
Heart failure 55%
Chronic kidney disease 52%
COPD 49%
Atrial fibrillation 45%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $4,415
$4,415 — —
AVYCAZ
  • AbbVie, Inc. $2,293
$2,293 — —
TEFLARO
  • AbbVie, Inc. $131
$131 — —
Fetroja
  • Shionogi Inc $37
$37 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record